OMA3
Today, OMA3™ (Open Metaverse Alliance), an association based in Zug, Switzerland, is announcing open membership to its first working groups at Web Summit, Europe’s largest tech conference.
Initial working group participants include some of the biggest and most innovative names in the space such as Animoca Brands, Alien Worlds, Dapper Labs, MetaMetaverse, SPACE Metaverse, SuperWorld, The Sandbox, Upland, Voxels, Unstoppable Domains, and Wivity (the agent to the consortium).
One of the core values of the metaverse is celebrating the decentralization of not only assets but power and influence as well. OMA3 achieves this by ensuring virtual land, identities, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities. OMA3’s Portaling and Mapping Working Group will create standards that allow users to port between virtual worlds. The Asset Transfer Working Group will standardize infrastructure for moving digital assets between virtual worlds. The Legal Working Group will examine the protection and fair use of intellectual property in Web3 applications and monitor developments in the regulatory environment. Companies wishing to participate in these working groups are invited to join OMA3 as a Creator Member on its website- OMA3.org.
As the metaverse continues to grow and develop at a rapid pace, the association will continue to nurture an open, interoperable metaverse by launching more working groups in areas such as participant safety, privacy, and cybersecurity.
Dirk Lueth, Co-founder & Co-CEO, Upland, Founding Member and Chairperson of OMA3 said, “The vision of OMA3 is to move from a platform-controlled Web2-world to a user-centric Web3-Metaverse. To achieve this, we have formed an alliance of Web3 companies who want to solve interoperability challenges for the metaverse, and we aim to leverage the alliance’s knowledge and web3 native insight to help propose and set the operating standard for interoperability in the metaverse.”
Batis Samadian, Founder & CEO, SPACE, Founding Member, and Vice Chair of OMA3 said, “Decentralization and interoperability require coordination to be successful. We are pleased that the OMA3 idea we hatched in the early days has resonated so well with the industry.”
All members of OMA3 have a shared belief in an Open Metaverse without restraining walls, where individual platforms are interconnected and fully interoperable so users can move their digital assets freely across worlds. To realize this goal, OMA3 has been formed and looks forward to members joining its mission.
Sébastien Borget, Co-Founder and COO of The Sandbox and Founding Member of OMA3 said, “within the Open Metaverse, digital assets freely move across OMA3 virtual worlds, enjoying increased security and better asset tracking across worlds. With these shared standards, users will be able to take digital items that they own from one metaverse to another, enabling a universe of interconnected virtual worlds that prioritizes user experience and ownership over platform dominance and censorship.”
Saro McKenna, CEO of Alien Worlds and Founding Member of OMA3 said, “OMA3’s vision centers on striving to create an open metaverse that is also community run, decentralized and indexable, where users will be able to own and use their digital assets (e.g. NFTs), identity and reputation in a frictionless way across multiple platforms. In OMA3’s vision users are in control of their assets, not platform owners, while ideas and services are based on the foundation of decentralization and interoperability to optimize for individual freedom, social, economic, and other sustainable outcomes.”
OMA3 is committed to ensuring data is permissionless, interoperable, and fully user-controlled, with DAO governance-centered principles of inclusiveness, transparency, and decentralization. As such, OMA3 is open to all Web3 metaverse builders; companies can join as creators or community members. To learn more about participation, please visit www.oma3.org.
About OMA3
OMA3, (Open Metaverse Alliance) is a consortium comprised of leading metaverse native companies The Sandbox, Animoca Brands, Alien Worlds, Dapper Labs, Decentraland, MetaMetaverse, Space, SuperWorld, Upland, Voxels, Unstoppable Domains, and Wivity. OMA3 seeks to ensure virtual land, digital assets, ideas, and services are highly interoperable between platforms and transparent to all communities.
Twitter: twitter.com/oma3dao
Website: www.oma3.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
